Pipeline

Novaliq offers an industry-leading drug portfolio

What products are next in the pipeline?

  • CyclASol®, an anti-inflammatory and immunomodulating drug for the treatment of dry eye disease (DED) with a demonstrated early onset of action and excellent tolerability, is evaluated in the pivotal ESSENCE phase 2b/3 study.
  • NOV03, the first drug addressing evaporative DED associated with meibomian gland dysfunction (MGD), is evaluated in the SEECASE phase 2 study.

Dry Eye Disease Rx Product Family

Glaucoma & Retina Development Programs

What clinical studies are currently under way?

  • Novaliq’s ESSENCE phase 2b/3 clinical study (NCT 03292809) is a pivotal randomized, double-masked, vehicle-controlled, multi-center trial, designed to evaluate the safety, efficacy and tolerability of topical CyclASol® for the treatment of DED. CyclASol®, has demonstrated better efficacy and tolerability versus current gold-standard RestasisTM in a US Phase 2 study.
  • Novaliq’s SEECASE clinical study (NCT 03333057) is a phase 2, multi-center, randomized, double-masked, saline-controlled study to evaluate the effect of NOV03 at two different dosing regimens on the signs and symptoms of evaporative DED. NOV03 is potentially the first DED drug treatment addressing MGD and evaporative-caused DED.

Results for both U.S. studies are anticipated in Q4 2018.

Start typing and press Enter to search